Risperdal Oral Formulation
Company: Janssen Pharmaceutica
Approval Status: Approved July 1996
Treatment for: schizophrenia
Areas: Psychiatry/Psychology
| General Information | Clinical Results |
General Information
Risperdal is indicated for the management of the manifestations of psychotic disorders, including both the positive symptoms (delusions, hallucinations, and hearing voices) and negative symptoms (diminished emotional expressions) of schizophrenia, schizoaffective disorder, and the psychotic features associated with bipolar disorder.
Clinical Results
Clinical studies have shown that extrapyramidal symptoms (EPS) with Risperdal, while dose dependent, is comparable to placebo at recommended doses. The most common side effects reported in clinical trials were insomnia, agitation, EPS, headache, anxiety and rhinitis; less common were somnolence, dizziness, constipation, nausea, and tachycardia. Risperdal may also cause orthostatic hypotension, a form of low blood pressure, especially during the initial dosing period.The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.



